Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
34.45 39.53 39.87 21.67
Net Debt/EBITDA
(0.31) (0.89) (1.47) (2.86)
Debt/Equity
0.70 0.74 0.77 0.79
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.56) (1.06) (0.20) (0.68)
Book value per Share
17.82 17.08 16.32 15.83
Free Cash Flow
(10.56) (7.08) (1.34) (4.64)
Other line items

Show all line items

Columns are period end dates